Opko Health: Expanding Pipeline and Strategic Partnerships Underpin Buy Rating and Long-Term Value Upside

Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on Opko Health and keeping the price target at $3.00.

Yi Chen has given his Buy rating due to a combination of factors related to Opko Health’s expanding pipeline and its strategic partnerships. He highlights the broadened collaboration with Entera Bio on a first-in-class oral long-acting parathyroid hormone therapy for hypoparathyroidism, which has shown encouraging preclinical PK/PD results and is being advanced toward an IND filing in late 2026.

Yi Chen also points to the progress of additional peptide programs, including injectable and oral oxyntomodulin, where Phase 1 data for the subcutaneous formulation are anticipated by the end of 2026, supporting longer-term value creation. Furthermore, he views the collaboration between ModeX and Regeneron on multispecific antibodies, with sizeable potential milestones and royalties, as strong external validation of Opko’s technology platform and a source of meaningful non-dilutive upside, underpinning his positive stance on the shares.